Influx HealthtechShare price, financial results, shareholding and management

NSE Emerge · INFLUXNutraceutical contract manufacturingListed 25 June 2025IPO ₹96Catch them young
influxhealthtech.com ↗Live price on NSE ↗ISIN INE0MYZ01012 · Lot 600 shares · ₹1.67 lakh
₹278.10
-0.30% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹644 cr
Stock P/E
31.3peers 21.3
Book value
₹43.5
Price to book
6.39
EV / operating profit
20.7
Market cap to sales
4.38
Returns and growth
ROCE · FY26
40.1%
ROE · FY26
30.0%
ROE, 3-year average
45.6%
Operating margin · FY26
20.3%peers 8.9%
Sales growth, 3 years
24.5%
Profit growth, 3 years
43.2%
Safety
Debt to equity
0.00peers 0.48
Borrowings
₹0 cr
Interest cover
152.3×
Cash from business / op. profit
13%
Debtor days
84
Pledged
0.00%
Ownership and share
Promoter holding
73.53%
Change in promoter holding
0.00 pts
Shareholders
1,335
52-week high / low
₹315 / ₹183
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Influx Healthtech share price chart

₹278.10+21.34% 1 year

Close on 19 Nov 2026 · -0.32% on the day · Vol 14,400

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+7.2%
3 months
-3.6%
6 months
+19.2%
1 year
+21.3%
Since IPO
+189.7%
Traded a day, 20 days
₹0.59 cr
Taken for delivery
78%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+40%+58%
3 years, a year+25%+43%
Latest half, H2 FY26+40%+32%

About Influx Healthtech: business, products and customers

Influx Healthtech makes health supplements, and some skin care, herbal, pet and home care products, for other companies that put their own brand names on them. It works from factories in Palghar, Maharashtra, and its shares trade on NSE Emerge.

Influx Healthtech is a contract maker: brand owners, from multinationals to young online brands, bring a product idea and the company develops the formula, makes it and handles the regulatory work. It offers tablets, capsules, powders, gummies, protein bars, liquids and sachets, and lists more than 3,400 products.

Nutraceuticals brought in 90% of FY26 revenue, with cosmetics, ayurvedic products and a small veterinary and home care line making up the rest. Production runs from four units in Palghar, one of them rented, holding certifications such as GMP, HACCP, Halal, ISO 22000 and NSF. Almost all sales are in India.

Read more about the business

What is new: a nutraceutical plant of about 75,000 sq ft on Plot No. 59, paid for from the June 2025 public issue, which the company says will lift installed capacity about two and a half times. It has also set up a subsidiary, Olahey Wellness, for ready to drink beverages, ordered a larger pet food line and received approvals to supply Tanzania and Nigeria.

From the offer document (red herring prospectus, June 2025), the annual report 2024-25, the May 2026 investor presentation and earnings call, and the April 2026 press release on the use of issue proceeds.

Read the deeper study ↓

In its favour

  • Sales have grown fast: 25% a year over three years.
  • It earns a high return on the money it uses: ROCE 40% in FY26.
  • It has little debt for its size: debt to equity 0.00.
  • The promoters own a large part of the company: 73.53%.

To watch

  • Start of the Plot No. 59 nutraceutical plant, which the managing director expected to be ready by July or August 2026 (Earnings call, May 2026, p.3 to 5; Press release, April 2026, p.4).
  • FY27 revenue growth against the company's guidance of 25% to 30% with similar margins (Investor presentation, May 2026, p.5).
  • The beverage line at Olahey Wellness and the 1,000 kg per hour pet food line, both ordered for FY27 (Investor presentation, May 2026, p.20; Earnings call, May 2026, p.4).
  • Share of revenue from the ten largest clients, 49% in FY26 (Investor presentation, May 2026, p.29).
  • Customers take longer to pay than before: 84 days in FY26, against 64 in FY22.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Influx Healthtech revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150Sales, FY22: 59 ₹ cr59Net profit, FY22: 4 ₹ cr4FY22Sales, FY23: 76 ₹ cr76Net profit, FY23: 7 ₹ cr7FY23Sales, FY24: 100 ₹ cr100Net profit, FY24: 11 ₹ cr11FY24Sales, FY25: 105 ₹ cr105Net profit, FY25: 13 ₹ cr13FY25Sales, FY26: 147 ₹ cr147Net profit, FY26: 20.5 ₹ cr20.5FY26
The latest halves, ₹ crore
SalesNet profit
0255075100Sales, H1FY25: 48 ₹ cr48Net profit, H1FY25: 6 ₹ cr6H1FY25Sales, H2FY25: 57 ₹ cr57Net profit, H2FY25: 8 ₹ cr8H2FY25Sales, H1FY26: 66.8 ₹ cr66.8Net profit, H1FY26: 10 ₹ cr10H1FY26Sales, H2FY26: 80.1 ₹ cr80.1Net profit, H2FY26: 10.6 ₹ cr10.6H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.

Influx Healthtech half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY25H2FY25H1FY26H2FY26
Sales485766.7680.07
Expenses394552.1064.87
Operating profit91114.6615.20
OPM19.0%20.0%22.0%19.0%
Interest0000.18
Depreciation121.682.09
Profit before tax81013.0714.16
Net profit6810.0110.55

Influx Healthtech profit and loss

Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY22FY23FY24FY25FY26
Sales5976100105146.83
Expenses53658384116.98
Operating profit611172129.86
OPM11.0%14.0%17.0%20.0%20.3%
Other income00001.33
Interest00000.18
Depreciation01233.78
Profit before tax610151827.23
Tax rate33.3%30.0%26.7%27.8%24.6%
Net profit47111320.54
EPS ₹1,8002,8804,4527.379.35
Dividend payout0.0%0.0%0.0%0.0%0.0%

The years to FY25 come rounded to the nearest crore in the source.

Earnings per share before FY25 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.

Influx Healthtech profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a high return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%10%20%30%FY22: 11.0%11.0%FY22FY23: 14.0%14.0%FY23FY24: 17.0%17.0%FY24FY25: 20.0%20.0%FY25FY26: 20.3%20.3%FY26
Per cent
FY22FY23FY24FY25FY26
Operating margin11.0%14.0%17.0%20.0%20.3%
Tax rate33.3%30.0%26.7%27.8%24.6%
ROCE·110.7%83.2%61.0%40.1%
ROE·87.2%62.7%44.0%30.0%
Dividend payout0.0%0.0%0.0%0.0%0.0%

Influx Healthtech debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. It has almost no borrowings. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
050100150Net worth, FY22: 4 ₹ cr4Borrowings, FY22: 1 ₹ cr1FY22Net worth, FY23: 12 ₹ cr12Borrowings, FY23: 1 ₹ cr1FY23Net worth, FY24: 23 ₹ cr23Borrowings, FY24: 0 ₹ cr0FY24Net worth, FY25: 36 ₹ cr36Borrowings, FY25: 0 ₹ cr0FY25Net worth, FY26: 101 ₹ cr101Borrowings, FY26: 0 ₹ cr0FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
0102030Cash from the business, FY22: 4 ₹ cr4Net profit, FY22: 4 ₹ cr4FY22Cash from the business, FY23: 7 ₹ cr7Net profit, FY23: 7 ₹ cr7FY23Cash from the business, FY24: 9 ₹ cr9Net profit, FY24: 11 ₹ cr11FY24Cash from the business, FY25: 7 ₹ cr7Net profit, FY25: 13 ₹ cr13FY25Cash from the business, FY26: 3.9 ₹ cr3.9Net profit, FY26: 20.5 ₹ cr20.5FY26

Bars below the line are cash going out.

Influx Healthtech balance sheet

At each 31 March · ₹ crore

₹ crore
FY22FY23FY24FY25FY26
Equity capital0.030.030.031823.15
Reserves412231877.61
Net worth4.0312.0323.0336100.76
Borrowings11000
Other liabilities12.9714.9717.973422.94
Total liabilities18284170123.70
Fixed assets36141927.58
Capital work in progress0000·
Investments00002.30
Other assets1522275193.82
Receivables····33.78
Inventory····15.93
Cash····25.17
Trade payables····19.12

Influx Healthtech cash flow

₹ crore

₹ crore
FY22FY23FY24FY25FY26
Cash from operations47973.89
Cash from investing-3-5-8-9-25.16
Cash from financing10-1044.53
Net cash flow220-223.26
Capital spending····24.56

Working capital

Days

Days
FY22FY23FY24FY25FY26
Debtor days64665811384
Inventory days141841112·
Days payable88123106248·
Cash conversion cycle-10-39-6-24·
Working capital days211546·

Influx Healthtech peers and competitors

Listed SME companies in the same industry

By sales, Influx Healthtech is number 8 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Infinium Pharmachem47138.719012.211.4%0.19
Zenith Drugs6817.21713.97.1%0.75
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech64431.314720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
KRM Ayurveda57328.61022030.0%0.00
Median of the 10 others11121.31305.78.9%0.48

Influx Healthtech shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Foreign and Indian funds own a noticeable share. The number of shareholders has come down.

Promoters
73.53%
0.00 pts since Jun 25
Foreign investors (FIIs)
0.16%
-3.22 pts since Jun 25
Indian institutions (DIIs)
5.65%
-4.81 pts since Jun 25
HNIs (over ₹2 lakh each)
6.53%
+6.53 pts since Jun 25
Small holders (up to ₹2 lakh)
9.60%
-1.29 pts since Jun 25
Companies and others
4.53%
+2.79 pts since Jun 25
Number of shareholders
1,335
2,403 in Jun 25

Influx Healthtech shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Jun 25Sep 25Mar 26
Promoters73.53%73.53%73.53%
Foreign investors (FIIs)3.38%1.83%0.16%
Indian institutions (DIIs)10.46%6.83%5.65%
HNIs (over ₹2 lakh each)0.00%5.64%6.53%
Small holders (up to ₹2 lakh)10.89%8.28%9.60%
Companies and others1.74%3.89%4.53%
Number of shareholders2,4031,0221,335

The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.

Influx Healthtech study: the business from its own documents

Read from 11 of the company's own documents

Influx Healthtech so far

From the company's own record

  1. 25 June 2025Listed on NSE Emerge at ₹96
  2. 31 March 2026Promoters at 73.53%
  3. 6 July 2026Highest close since listing, ₹312.35

Influx Healthtech key facts from the filings

Each figure with the document it comes from

Revenue growth
40%
FY26 revenue rose to ₹146.8 cr from ₹104.9 cr, after only about 5% growth in FY25 when the plants were running at full capacity.Investor presentation, May 2026, p.31; Annual report 2024-25, p.53
Top ten clients
49%
Share of FY26 revenue from the ten largest clients, about the same as in the two years before.Investor presentation, May 2026, p.29
Clients served
718
Number of clients in FY26, up from 636 in FY25; the company puts client retention at 98%.Investor presentation, May 2026, p.4 and p.16; Earnings call, May 2026, p.4
Capacity used
70%
Share of capacity in use in FY26 after new lines were added, against 89% in FY25.Investor presentation, May 2026, p.4
New plant
75,000 sq ft
Nutraceutical facility on Plot No. 59, enlarged from about 35,000 sq ft; the managing director said in May 2026 it should be ready by July or August 2026.Earnings call, May 2026, p.3 to 5; Press release, April 2026, p.3
Show 5 more facts
Issue money used
45.6%
Share of the ₹43.4 cr of issue proceeds for stated objects used by 31 March 2026; ₹10.1 cr was moved from the veterinary plant and machinery to the nutraceutical building.Press release, April 2026, p.2
Cash from operations
₹3.9 cr
Operating cash flow in FY26 against profit after tax of ₹20.5 cr, as trade payables fell by ₹10.3 cr.Investor presentation, May 2026, p.31 and p.33
Second half margin
19.0%
EBITDA margin in the second half of FY26, down from 20.2% a year earlier, as material costs and new hires rose.Investor presentation, May 2026, p.31; Earnings call, May 2026, p.4 and p.8
Product range
3,428
Products made in FY26, across supplements, cosmetics, ayurvedic, veterinary and home care lines.Investor presentation, May 2026, p.4
Borrowings
Nil
No borrowings at March 2026, with cash of ₹25.2 cr; the managing director said no debt is planned for the expansion.Investor presentation, May 2026, p.32; Earnings call, May 2026, p.21 and p.22

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company guides for FY27 revenue growth of 25% to 30% with similar margins. On the May 2026 call, Managing Director Munir Chandniwala said the new Plot No. 59 plant should be ready by July or August 2026, that it could add about ₹40 cr to ₹50 cr of revenue in FY27, and that the company aims for revenue of about ₹450 cr to ₹500 cr by FY29. The April 2026 press release said the enlarged construction should finish within about 180 days of shareholder approval.

25% to 30%FY27 growth guidanceWith similar margins, May 2026
75,000 sq ftNew nutraceutical plantExpected ready July or August 2026
About 2.5 timesInstalled capacity after the plantAs stated by the company
What management saidWhenWhat happened
A sharp rise in orders in FY26, with stock built in March 2025 for itAnnual report 2024-25FY26 revenue up 40%, to ₹146.8 cr
Capacity raised 25% to 30% before using issue proceedsMay 2026 presentationCapsule, tablet and liquid lines added in H1 FY26 from internal accruals

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Influx Healthtech earns its money making supplements and other health products to order for brand owners, and has kept steady margins while growing.

Its weak spots are a handful of large clients who bring in about half the sales and push for lower prices, and a big new plant that still has to be filled.

AverageCan it set its own prices?Prices are set on a cost plus basis, so higher material costs are passed on, but only after a lag, and large clients pay thinner margins.
The evidence. The managing director said the company follows cost plus pricing with a lag, that bigger clients squeeze margins and smaller ones balance them. EBITDA margin was 20.3% in FY26 against 19.6% in FY25.Earnings call, May 2026, p.8, p.9 and p.12; Investor presentation, May 2026, p.31
AverageHow strong is it against rivals?Its strengths are a very wide product range, small and large batch sizes and in house design, regulatory and printing support, but the documents give no market share.
The evidence. More than 3,400 products, certifications including GMP, HACCP, Halal, ISO 22000 and NSF, and an in house formulation team of eight. The managing director said the company offers the widest range of nutraceutical and cosmetic products to clients.Investor presentation, May 2026, p.8 and p.14; Earnings call, May 2026, p.19
WatchWho are its customers?Hundreds of brand owners, most of whom stay, but the ten largest bring in about half the revenue.
The evidence. The top ten clients gave 49% of FY26 revenue (47.89% in FY25). The company served 718 clients in FY26 with 98% retention; Novus Lifesciences and Octavius were named as the two largest.Investor presentation, May 2026, p.4, p.16 and p.29; Offer document, p.192; Earnings call, May 2026, p.11
AverageDoes it need a lot of money?Growth needs new plants and machines, which the issue money is paying for, and in FY26 little of the profit turned into cash.
The evidence. Capital spending was ₹25 cr in FY26 and operating cash flow ₹3.9 cr against profit of ₹20.5 cr. There were no borrowings at March 2026.Investor presentation, May 2026, p.29, p.32 and p.33
AverageCan it keep finding new work?There are no long term contracts, so work comes order by order, though existing clients keep growing and new names keep joining.
The evidence. The managing director said the industry has no long term contracts; the largest client gives a three month projection and the second largest a one year plan. Client numbers rose from 538 in FY23 to 718 in FY26.Earnings call, May 2026, p.11; Investor presentation, May 2026, p.16
AverageDo good and bad years swing a lot?Demand for supplements has been steady, but growth stalls when the plants are full and margins move with material costs and the client mix.
The evidence. Revenue grew about 5% in FY25 while the company ran at maximum capacity, then 40% in FY26 after new lines were added. Gross margin fell in the second half of FY26 as packaging and solvent costs rose.Annual report 2024-25, p.53; Investor presentation, May 2026, p.31; Earnings call, May 2026, p.7 to 9

Who runs Influx Healthtech?

Promoters, directors and officers; tap a name for the background

MAMunir Abdul Ganee ChandniwalaPromoter, Chairman and Managing Director · holds 69.73%

Founder of the company. Holds a Bachelor of Pharmacy from the University of Pune, a post graduate degree in Management and Business Administration and a Doctor of Philosophy programme, and is a registered pharmacist with the Maharashtra State Pharmacy Council. About 22 years in nutraceutical, cosmetic, ayurvedic and home care manufacturing; ran Influx Healthcare, a sole proprietorship in third party manufacturing, from 2002.

Offer document, p.228, p.241 and p.247; Investor presentation, May 2026, p.23
SMShirin Munir Ahmed ChandniwalaPromoter and Whole-Time Director · holds 3.80%

Co-founder with a Bachelor of Commerce from Hemchandracharya North Gujarat University and more than 12 years in trading of packaging materials, as a partner of Shinaf Enterprise since 2012. Looks after financial management, data analysis and budgets. The offer document states that Shirin Munir Ahmed Chandniwala is the spouse of Munir Abdul Ganee Chandniwala.

Offer document, p.228 to 230 and p.247
AGAbdul Ganee Abdul Rasul ChandniwalaPromoter and Non-Executive Director

Holds a Diploma of Licentiate of the Court of Examiners of Homeopathic and Biochemic Systems of Medicine and a certificate in Modern Pharmacology, with about 21 years in the pharmaceutical industry. The offer document states that Abdul Ganee Abdul Rasul Chandniwala is the father of Munir Abdul Ganee Chandniwala, and notes that the company could not document earlier years of experience.

Offer document, p.229, p.230 and p.247
VBVipul Balubhai PatelIndependent Director

A doctor with an MBBS and an MD in Pathology, a member of the Maharashtra Medical Council, and founder director of Sunflower Laboratory & Diagnostic Center in Mumbai since 1998; 26 years in healthcare.

Offer document, p.229; Investor presentation, May 2026, p.23
MSMohmad Saleh MutvalliIndependent Director

A Chartered Accountant and member of ICAI with experience in taxation, accounting and compliance, listed as an Independent Director in the May 2026 investor presentation.

Investor presentation, May 2026, p.23
AGAshish Ghanshyam ShahChief Financial Officer

Bachelor of Commerce from the University of Mumbai with more than 20 years in accounts and finance, including work at Konark Synthetic; Chief Financial Officer since May 2024.

Offer document, p.229, p.241 and p.242

Influx Healthtech latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹80.1 cr (+40%), net profit ₹10.6 cr (+32%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters unchanged at 73.53%; Aarth AIF Growth Fund down to 1.40%.

Influx Healthtech annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Influx Healthtech share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Influx Healthtech's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (2,31,50,400 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • !Earnings per share changes basis between FY24 (₹4,452.00) and FY25 (₹7.37) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY22 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Influx Healthtech

What does Influx Healthtech do?

Influx Healthtech makes health supplements, and some skin care, herbal, pet and home care products, for other companies that put their own brand names on them. It works from factories in Palghar, Maharashtra, and its shares trade on NSE Emerge.

What is the share price of Influx Healthtech?

₹278 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Influx Healthtech?

₹644 cr at the close on 19 Nov 2026, on 2,31,50,400 shares.

What is the P/E of Influx Healthtech?

31.3 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Influx Healthtech's revenue and profit?

Revenue ₹147 cr and profit after tax ₹21 cr in FY26.

Who are the promoters of Influx Healthtech?

Munir Abdul Ganee Chandniwala, Shirin Munir Ahmed Chandniwala, Abdul Ganee Abdul Rasul Chandniwala; promoters held 73.53% at 31 March 2026.

What was the IPO price of Influx Healthtech?

₹96 a share; it listed on 25 June 2025.

What is Influx Healthtech's website?

www.influxhealthtech.com

More SME companies like Influx Healthtech

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2025 →

Built from 3 earnings call transcripts, 3 investor presentations, 2 annual reports, 1 offer document, 1 result filing, 1 press release, 83 exchange announcements, 3 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.